Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moleculin Biotech (MBRX) Change in Accured Expenses (2016 - 2025)

Moleculin Biotech (MBRX) has 10 years of Change in Accured Expenses data on record, last reported at -$549000.0 in Q3 2025.

  • For Q3 2025, Change in Accured Expenses fell 535.71% year-over-year to -$549000.0; the TTM value through Sep 2025 reached $80000.0, down 92.26%, while the annual FY2024 figure was -$1.1 million, 174.31% down from the prior year.
  • Change in Accured Expenses reached -$549000.0 in Q3 2025 per MBRX's latest filing, down from -$390000.0 in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $2.4 million in Q4 2023 and bottomed at -$1.1 million in Q1 2024.
  • Average Change in Accured Expenses over 5 years is $47578.9, with a median of $44000.0 recorded in 2022.
  • The widest YoY moves for Change in Accured Expenses: up 3330.67% in 2023, down 1611.36% in 2023.
  • A 5-year view of Change in Accured Expenses shows it stood at $11000.0 in 2021, then crashed by 781.82% to -$75000.0 in 2022, then surged by 3330.67% to $2.4 million in 2023, then crashed by 88.4% to $281000.0 in 2024, then tumbled by 295.37% to -$549000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Accured Expenses were -$549000.0 in Q3 2025, -$390000.0 in Q2 2025, and $738000.0 in Q1 2025.